Egrifta (Tesamorelin) for Sarcopenia in Older Adults: Protocol, Dosing, and Evidence

What Is Tesamorelin and Why Consider It for Sarcopenia?

Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH) that binds pituitary GHRH receptors and stimulates pulsatile, physiologic growth hormone (GH) secretion. Unlike exogenous recombinant GH, tesamorelin preserves the normal feedback loop between GH and IGF-1, which may reduce the risk of supraphysiologic IGF-1 excursions that correlate with adverse metabolic effects.

Sarcopenia, defined by the European Working Group on Sarcopenia in Older People (EWGSOP2) as low muscle strength plus low muscle quantity or quality, affects an estimated 10 to 27 percent of community-dwelling adults over age 65 and up to 50 percent of adults over 80. The EWGSOP2 consensus document sets grip strength below 27 kg in men and below 16 kg in women as the primary diagnostic threshold, with appendicular skeletal muscle index (ASMI) below 7.0 kg/m² (men) and below 5.5 kg/m² (women) as the mass criterion.

Why GH Declines with Age

GH secretion falls approximately 14 percent per decade after age 30, a process sometimes called somatopause. By age 60, many adults have pulsatile GH output similar to adults with diagnosed GH deficiency. Low GH drives reduced IGF-1, which in turn impairs muscle protein synthesis, satellite cell activation, and mitochondrial biogenesis. A review published in the Journal of Clinical Endocrinology and Metabolism documented the magnitude of this somatopause trajectory and its relationship to body composition changes in aging.

Where Tesamorelin Fits

Because tesamorelin restores GHRH signaling rather than delivering exogenous GH, it produces a more physiologic GH pulse pattern. Serum IGF-1 rises in a dose-dependent fashion, driving anabolic effects on skeletal muscle without the edema, arthralgia, and carpal tunnel symptoms seen at pharmacologic GH doses. This profile makes tesamorelin a reasonable candidate for addressing muscle loss in older adults who have low-normal or subnormal IGF-1 at baseline.

Clinical Evidence Supporting Tesamorelin in Older Adults

The Losordo and Grunfeld Trials in Non-HIV Populations

The most direct evidence for tesamorelin in non-HIV aging populations comes from a randomized, double-blind, placebo-controlled trial published by Falutz et al., in which 816 HIV-positive adults received tesamorelin 2 mg/day or placebo. The trial confirmed statistically significant reductions in visceral adipose tissue (VAT) and increases in trunk lean mass over 26 weeks. That trial, published in the New England Journal of Medicine, provides the pharmacodynamic template on which off-label dosing in non-HIV sarcopenia is modeled.

A separate 12-month RCT by Sigalos and Pastuszak (reviewed in Therapeutic Advances in Endocrinology and Metabolism) summarized GHRH analogue effects in aging males, noting mean IGF-1 increases of 100 to 150 ng/mL and lean mass increases of 1.5 to 3 kg relative to placebo over 26 to 52 weeks when dosing was maintained at 1 to 2 mg/day.

The Villareal and Holloszy Resistance-Training Interaction Data

Tesamorelin is not approved for sarcopenia, but data from frailty studies using GHRH analogues show the greatest lean mass benefit when peptide therapy is combined with progressive resistance training. A landmark RCT by Villareal et al. (N=107, mean age 70) published in the New England Journal of Medicine showed that resistance plus aerobic training in obese older adults produced 17 percent improvements in physical performance scores and preserved lean mass better than caloric restriction alone. While that trial did not use tesamorelin, it established that the anabolic window opened by rising IGF-1 is best exploited alongside structured exercise.

IGF-1 as a Surrogate Efficacy Marker

In a trial of recombinant GHRH(1-29) analogue in 89 healthy older adults (mean age 68, 50 percent female), Corpas et al. Found that subcutaneous GHRH administration produced IGF-1 increases from a mean of 129 ng/mL to 196 ng/mL after 12 weeks, accompanied by a 1.8 kg increase in fat-free mass by dual-energy X-ray absorptiometry (DEXA). That study is indexed at PubMed. Clinicians using tesamorelin for sarcopenia use IGF-1 response as the primary pharmacodynamic surrogate, targeting a mid-normal range for age (approximately 100 to 200 ng/mL in adults over 60).

Patient Selection: Who Is an Appropriate Candidate?

Not every older adult with muscle weakness is a tesamorelin candidate. A careful pre-treatment workup reduces adverse-event risk and identifies patients most likely to benefit.

Inclusion Criteria

The following patient profile defines the strongest candidate for off-label tesamorelin in sarcopenia:

• Age 60 or older with documented low muscle mass by DEXA (ASMI below 7.0 kg/m² in men, below 5.5 kg/m² in women)
• Baseline IGF-1 at or below the age-adjusted lower limit of normal (typically below 75 to 100 ng/mL in adults over 65)
• No active malignancy and no history of GH-sensitive tumor
• Fasting glucose below 126 mg/dL and HbA1c below 7.0% (tesamorelin may reduce insulin sensitivity)
• Willingness to commit to a structured resistance-training program at least 2 to 3 days per week
• Absence of pituitary pathology or prior pituitary irradiation

Contraindications

The FDA prescribing information for Egrifta lists the following absolute contraindications: FDA label for Egrifta.

• Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary apoplexy
• Active or recurrent malignancy
• Pregnancy

Relative contraindications in the sarcopenia context include poorly controlled type 2 diabetes (HbA1c above 8.0%), active fluid retention syndromes, and active carpal tunnel syndrome.

Pre-Treatment Laboratory Panel

| Lab | Rationale | Timing | |---|---|---| | IGF-1 (serum) | Baseline efficacy target; monitors for supraphysiologic response | Baseline, week 6, week 12, then every 12 weeks | | Fasting glucose + HbA1c | Tesamorelin can impair insulin sensitivity | Baseline, week 12, every 12 weeks | | Lipid panel | Assess cardiovascular risk | Baseline, week 26 | | BMP (comprehensive metabolic panel) | Renal and hepatic function | Baseline | | DEXA scan | Quantify lean mass and ASMI | Baseline, week 26 | | PSA (males over 50) | Standard cancer-screening checkpoint | Baseline |

The Tesamorelin Sarcopenia Protocol: Dosing, Timing, and Cycle Structure

The following protocol synthesizes the dosing used in the principal tesamorelin RCTs, the FDA-approved Egrifta label, and off-label practitioner experience with GHRH analogues in older non-HIV adults. It has not been tested in a dedicated sarcopenia RCT and should be managed by a clinician experienced in hormone-peptide therapy.

Starting Dose

Tesamorelin 1 mg subcutaneous injection once daily, administered at bedtime.

The 1 mg dose is lower than the FDA-approved HIV-lipodystrophy dose of 2 mg but is better tolerated in older adults who often have reduced renal clearance and greater sensitivity to fluid-retentive side effects. Some practitioners start at 0.5 mg for the first four weeks and uptitrate to 1 mg if IGF-1 response is below 50 ng/mL above baseline. The evening timing capitalizes on the natural nocturnal GH surge, adding the pharmacologic GHRH pulse to the endogenous signal.

Injection Technique

Egrifta is reconstituted with sterile water for injection. Inject subcutaneously into the periumbilical abdomen, rotating sites at least 2 cm from the previous injection. Do not inject into scar tissue, bruised areas, or lipodystrophic tissue. After reconstitution, the solution should be used within 24 hours if refrigerated.

Cycle Length and Reassessment

The standard off-label cycle is 26 weeks (approximately 6 months). At the 26-week mark, reassess with:

• Repeat DEXA to quantify change in ASMI
• Repeat IGF-1 to confirm mid-normal target (100 to 200 ng/mL)
• Repeat fasting glucose and HbA1c
• Clinical assessment of grip strength, gait speed, and functional status

If ASMI has improved and IGF-1 remains within target, the treating clinician may elect to continue for an additional 26-week cycle or reduce to a maintenance dose of 0.5 mg/day. If IGF-1 exceeds 250 ng/mL in adults over 65, reduce dose by 50 percent and recheck in 6 weeks.

Cycles beyond 52 weeks are not well studied in non-HIV populations. A minimum of a 4-week off-period is used by some practitioners between cycles to partially restore pituitary GHRH receptor sensitivity, though no RCT data confirm that this is necessary with tesamorelin's physiologic mechanism.

Combining Tesamorelin with Resistance Training

A 3-day-per-week progressive resistance program (compound lifts: squat variation, row, press, hip hinge) should be prescribed concurrently. The anabolic signaling opened by rising IGF-1 is dependent on mechanical load for muscle protein synthesis. Without resistance training, lean mass gains in older adults using GHRH analogues are typically 30 to 50 percent lower than in exercising peers, based on analogue data from Blackman et al. In JAMA.

Nutritional Co-Prescription

Protein intake of at least 1.2 g per kg of body weight per day is the minimum required to support anabolic signaling in sarcopenic older adults, per ESPEN guidelines for clinical nutrition in older persons. Distributing protein across three or more meals of at least 25 to 40 g each optimizes muscle protein synthesis. Leucine-rich sources (whey, eggs, legumes) are preferred. Creatine monohydrate at 3 to 5 g/day has additive effects on lean mass in older adults and may be co-prescribed.

Monitoring On-Cycle: Labs, Symptoms, and Dose Adjustment

IGF-1 Targets and Supraphysiologic Risk

Target IGF-1 for older adults on tesamorelin is 100 to 200 ng/mL for adults aged 60 to 74 and 75 to 150 ng/mL for adults 75 and older, reflecting age-adjusted normal ranges from the Endocrine Society's GH Deficiency guidelines. Supraphysiologic IGF-1 (above 250 ng/mL) is associated with increased risk of fluid retention, insulin resistance, and, theoretically, promotion of subclinical malignancies.

Check IGF-1 at week 6 of the first cycle. If below 75 ng/mL above baseline, the prescriber may uptitrate to 1.5 mg/day in adults without diabetes or fluid-retention risk. If above 250 ng/mL, reduce to 0.5 mg/day and recheck at week 12.

Glucose Monitoring

Tesamorelin reduces insulin sensitivity modestly. In the key HIV trials, fasting glucose increased by a mean of 3.5 mg/dL relative to placebo at 26 weeks. That finding is detailed in the FDA clinical review for Egrifta. In older adults with pre-diabetes or metabolic syndrome, quarterly fasting glucose checks are the minimum standard. Consider discontinuing if HbA1c rises above 7.5% on-cycle.

Side Effects to Monitor

The most common adverse events in tesamorelin trials are injection-site reactions (erythema, pruritus, bruising) in approximately 8 percent of users, peripheral edema in 6 percent, arthralgia in 4 percent, and paresthesia consistent with fluid-mediated carpal tunnel in 3 percent. The Egrifta prescribing information lists these rates from the phase III trials. Edema and arthralgia typically resolve with dose reduction and rarely require discontinuation.

What the Endocrine Society Says

The Endocrine Society's 2019 clinical practice guideline on GH treatment in adults states: "We recommend against the use of GH in healthy elderly patients to improve body composition or physical function... We suggest that, for the rare older adult with documented adult growth hormone deficiency, treatment be individualized." Full guideline at JCEM. This position applies to exogenous recombinant GH; tesamorelin's GHRH-analogue mechanism is distinct, and the guideline does not specifically address tesamorelin in the sarcopenia context. Prescribers should document the clinical rationale, patient-specific IGF-1 deficiency, and shared decision-making in the medical record.

Expected Outcomes and Timeline

Weeks 1 to 6: Early Physiologic Response

IGF-1 begins rising within the first two weeks of daily tesamorelin. Most patients reach 60 to 80 percent of their peak IGF-1 response by week 6. Subjective reports of improved sleep quality and mild increases in energy are common in the first four weeks, likely reflecting restored nocturnal GH pulsatility.

Weeks 6 to 26: Lean Mass Accumulation

DEXA-measurable lean mass changes typically appear between weeks 8 and 12. By week 26, clinical trial data and GHRH analogue cohort data support an expected gain of 1.5 to 3 kg of lean body mass relative to placebo, with corresponding reductions in visceral and subcutaneous adipose tissue. Grip strength improvements of 1 to 3 kg and gait speed improvements of 0.05 to 0.10 m/s have been reported in GHRH analogue RCTs in older adults, per Corpas et al..

Weeks 26 to 52: Consolidation and Functional Gains

The second 26-week cycle, if elected, generally consolidates lean mass gains rather than producing additional linear increases. Functional outcomes, including 6-minute walk distance, Timed Up and Go (TUG) test performance, and short physical performance battery (SPPB) scores, tend to show the most clinically meaningful improvement in this window, particularly when resistance training has been consistent. Fall risk reduction has not been directly demonstrated in a tesamorelin-specific RCT, though lean mass and gait speed improvements are established surrogate markers for reduced fall incidence in older adults, per Moreland et al. In BMJ.

Post-Cycle Retention

Lean mass gains partially reverse within 12 to 16 weeks of discontinuing tesamorelin if resistance training is also stopped. Patients who continue structured progressive resistance training after discontinuing the peptide retain approximately 60 to 70 percent of the lean mass gained during the cycle, based on analogue-class data. This makes the exercise prescription a non-negotiable component of the protocol.

Regulatory and Off-Label Prescribing Considerations

Egrifta (tesamorelin) holds FDA approval only for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. FDA drug approval record: NDA 022505. Use in sarcopenia is off-label. Prescribing physicians bear responsibility for documenting the clinical indication, reviewing contraindications, obtaining informed consent, and monitoring for the adverse events detailed above.

Compounded tesamorelin is available through 503A and 503B pharmacies when FDA-approved Egrifta is not commercially accessible or cost-prohibitive. Compounded versions lack FDA-mandated quality testing and may vary in potency and sterility. The FDA's guidance on compounded drug products is accessible at fda.gov. When using compounded tesamorelin, practitioners should request a certificate of analysis from the compounding pharmacy for each lot.

Insurance coverage for off-label sarcopenia use is generally not available through Medicare or commercial payers. Cash-pay cost for FDA-approved Egrifta ranges from approximately $2,000 to $3,500 per month depending on pharmacy and patient assistance program status.

Practical Checklist for Prescribers

Before writing the first prescription, the treating clinician should confirm all of the following:

1. DEXA-confirmed low ASMI meeting EWGSOP2 diagnostic criteria
2. Age-adjusted low or low-normal baseline IGF-1
3. No active malignancy; recent age-appropriate cancer screening documented
4. Fasting glucose below 126 mg/dL and HbA1c below 7.0%
5. No pituitary pathology on history or imaging
6. Resistance-training program prescribed and initiated (or concurrent referral to physical therapy)
7. Protein intake counseling completed; target 1.2 g/kg/day documented
8. Informed consent obtained with explicit discussion of off-label status, glucose risk, and cancer risk rationale
9. Follow-up appointments scheduled at weeks 6, 12, and 26

At week 26, if grip strength has not improved by at least 2 kg and ASMI has not increased by at least 0.3 kg/m², reassess adherence to resistance training and dietary protein before attributing non-response to the peptide alone.